Document Detail


Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
MedLine Citation:
PMID:  16387567     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Erectile dysfunction (ED) is highly prevalent in patients with chronic heart failure (CHF) and is among the most distressing symptoms in this patient population. Although the safety and efficacy of phosphodiesterase 5 (PDE5) inhibitors in the management of ED have been evaluated in many cardiovascular disease populations, scant data are available in patients with CHF. In published studies, the short-term safety and efficacy of sildenafil in patients with stable mild-to-moderate CHF with ED appears to be comparable to that observed in other populations with cardiovascular disease. Evidence is not available on the effects of vardenafil or tadalafil in CHF. In addition to their benefits in the treatment of ED, preliminary studies suggest that PDE5 inhibitors enhance endothelial function in patients with CHF and have beneficial effects on pulmonary hemodynamics and exercise capacity in patients with pulmonary hypertension. Additional studies are needed to determine the therapeutic potential of this class of agents in these disease states.
Authors:
Milan D Patel; Stuart D Katz
Related Documents :
1964577 - Effects of short-term administration of dobutamine on left ventricular performance, exe...
11591357 - Perindopril treatment for congestive heart failure.
7010897 - Review article. congenital complete heart block.
22315507 - Deoxyribonuclease is a potential counter regulator of aberrant neutrophil extracellular...
21831447 - Qt variability among weight-restored patients with anorexia nervosa.
19823987 - Differentiating the frontal variant of alzheimer's disease.
Publication Detail:
Type:  Journal Article; Review     Date:  2005-12-05
Journal Detail:
Title:  The American journal of cardiology     Volume:  96     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2006-01-02     Completed Date:  2006-03-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  47M-51M     Citation Subset:  AIM; IM    
Affiliation:
Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3',5'-Cyclic-GMP Phosphodiesterases
Chronic Disease
Cyclic Nucleotide Phosphodiesterases, Type 5
Endothelium, Vascular / drug effects,  enzymology,  physiopathology
Erectile Dysfunction / drug therapy,  enzymology,  epidemiology,  etiology
Heart Failure / drug therapy*
Humans
Hypertension, Pulmonary / drug therapy*,  enzymology,  epidemiology,  etiology
Male
Phosphodiesterase Inhibitors / adverse effects,  therapeutic use*
Phosphoric Diester Hydrolases / drug effects*
Chemical
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; EC 3.1.4.-/Phosphoric Diester Hydrolases; EC 3.1.4.35/3',5'-Cyclic-GMP Phosphodiesterases; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5; EC 3.1.4.35/PDE5A protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-bloc...
Next Document:  Relation of endothelial cell function to erectile dysfunction: implications for treatment.